genital herpes oral herpes B00
Conditions
Interventions
Group 1: subjects without HSV infection (PBMC samples already present)
analytic only
Group 2: HSV-2 infected subjects
single blood draw
Group 3: HSV-1 + HSV-2 infected subjects
Sponsors
Heidelberg ImmunoTherapeutics GmbH
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: The subject is at least 18 years old and capable of giving consent. Present consent to participate in the study. Proven seropositivity for HSV-2 or HSV-2 and HSV-1 combined.
Exclusion criteria
Exclusion criteria: Any disease or condition that does not medically permit blood sampling in the opinion of the physician providing information. Positive serostatus for HIV, hepatitis B or hepatitis C. Previous treatment with the antibody HDIT 101 (former MATCH-2 study patients who received placebo may be included). Vaccination with an HSV 1/2 vaccine (e.g. experimental)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Differences in the strength and specificity of T-cell responses against inactivated HSV-2 between the three groups: 1. subjects without HSV infection (PBMC samples already present), 2. HSV-2 infected subjects, and 3. HSV-1 + HSV-2 infected subjects. Evaluation after the single blood draw. | — |
Secondary
| Measure | Time frame |
|---|---|
| HLA-specific differences in the strength and specificity of T-cell responses to inactivated HSV-2 within the groups: 1. subjects without HSV infection (PBMC samples already present), 2. HSV-2 infected subjects, and 3. HSV-1 + HSV-2 infected subjects. Evaluation after the single blood draw. | — |
Countries
Germany
Contacts
Public ContactAnja Potthoff
WIR Zentrum für Sexuelle Gesundheit und Medizin Katholisches Klinikum Bochum Standort St. Elisabeth-Hospital
Outcome results
None listed